Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: Experience from the MIRACEL study

International Journal of Clinical Practice

Volumn 65, Issue 1, 2011, Pages 64-72

  Dellanna, F ^a   Winkler, R E ^b   Bozkurt, F ^b   Schettler, V ^c   Graf, S ^d   Bockreiss, N ^e   Fliser, D ^f  

^a Dialysezentrum Karlstrasse 17 19   (Germany)

^b Gemeinschaftspraxis für Innere Medizin   (Germany)

^c Nephrologisches Zentrum Gottingen   (Germany)

^d KfH Nierenzentrum   (Germany)

^e KfH Nierenzentrum   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG SCREENING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYRINGE;

EID: 78650425833     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02551.x     Document Type: Article

References (23)

1. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 94-111.
2. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB,. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003; 64: 1514-21.
3. Fishbane S, Berns JS,. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68: 1337-43.
4. Collins AJ, Brenner RM, Ofman JJ, et al. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005; 46: 481-8.
5. Wish J, Coyne DW,. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. Mayo Clin Proc 2007; 82: 1371-80.
6. Richardson D,. Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant 2002; 17 (Suppl. 1): 53-9.
7. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD,. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003; 42: 864-81.
8. Macdougall IC,. Individualizing target haemoglobin concentrations- tailoring treatment for renal anaemia. Nephrol Dial Transplant 2001; 16 (Suppl. 7): 9-14.
9. Nurko S, Spirko R, Law A, Dennis VW,. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study. N Clin Ther 2007; 29: 2010-21.
10. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47 (Suppl. 3): S1-70.
11. Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 1211-5.
12. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin beta. Clin Pharmacol Ther 1991; 50: 702-12.
13. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-5.
14. Locatelli F, Villa G, De Francisco ALM, et al., BA16286 Study Investigators. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis. Curr Med Res Opin 2007; 23: 969-79.
15. Levin NW, Fishbane S, Cañedo FV, et al., MAXIMA Study Investigators Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370: 1415-21.
16. Sulowicz W, Locatelli F, Ryckelynck JP, et al., PROTOS Study Investigators Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2: 637-46.
17. Fliser D, Kleophas W, Dellana F, et al. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin 2010; 26: 1083-9.
18. Pfeffer MA, Burdmann EA, Chen C-Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New Engl J Med 2009; 361: 2019-32.
19. Szczech La, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-8.
20. Solomon SE, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363: 1146-55.
21. Locatelli F, Aljama P, Bárány P, et al. European Best Practice Guidelines Working Group. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 (Suppl. 2): ii1-47.
22. Drüeke T,. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 2001; 16 (Suppl. 7): 25-8.
23. Institute of Medicine Committee on Identifying and Preventing Medication Errors, Board on Health Care Services. Preventing medication errors. (accessed August 23, 2010).